Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • In many places, new variants now represent the dominant form of the COVID-19 virus due to their higher transmissibility, leading to faster infection rates
  • Continuous monitoring through widespread testing will remain an essential component of the global COVID-19 response
  • Fionet’s combination of software and hardware is compatible with multiple COVID-19 test types from various manufacturers
  • Relay Medical is focused on novel technologies in the diagnostics and AI data science sectors
  • The Fionet Platform is an end-to-end, rapid testing and tracking solution
  • Fio Corporation developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings
  • Relay Medical is focused on novel technologies in the diagnostics and AI data science sectors
  • Relay Medical Corp (RELA) opened trading at C$0.54 per share

Relay Medical (RELA) and Fio Corp through their joint venture company Fionet Rapid Response Group report on recent COVID-19 related news.

Difficulties in the gradual roll-out of vaccines and the continued threat of novel variants across the globe mean that widespread, affordable, and accurate diagnostic testing remains a critical component to the global COVID response.

With the deployment of vaccines occurring at varying rates around the world, communities are still at risk of the virus spreading and hotspots re-emerging. Testing will remain a vital tool for controlling the pandemic and safely opening up economies.

“Communities have made great progress against COVID-19, but as we’ve seen this is an evolving epidemic that requires multiple tools to manage it. Now is the time to expand the global rapid affordable screening infrastructure to ensure we are in a better position to control the pandemic,” said Yoav Raiter, CEO, Relay Medical Corp.

The continued presence of COVID-19 in the population leaves the possibility for the development of new variants that may evade current vaccines, leaving the global community at risk of further waves of infection. For this reason, the Pfizer CEO expects a third shot may be necessary within a year from the first dose. 

In many places, new variants now represent the dominant form of the COVID-19 virus due to their higher transmissibility, leading to faster infection rates.

Combined with the unknown long-term protection provided by current vaccines, continuous monitoring of active infections and immunity, through widespread testing, will remain an essential component of the global COVID-19 response.

The Fionet platform can also support antibody testing to verify that vaccinated populations are still immune.

“The virus is evolving genetically, so testing programs must evolve technologically. Our platform enabled lab-quality testing at Toronto Pearson Airport – an unimagined requirement a year ago. Pandemic-capable viruses are becoming a normal part of life. For us to live a normal life in this circumstance, we need technology to enable workplaces, entertainment venues, transportation hubs, and homes to function normally,” said Michael Greenberg, CEO, Fionet Rapid Response Group and of Fio Corporation.

Fionet is a comprehensive, mobile testing and tracking platform to manage rapid testing programs at mass scale. It brings quality control, flexibility, and high throughput to rapid diagnostic tests in community settings.

The Fionet Platform also captures and distributes frontline testing and triage data instantly across organizations, enabling timely, data-informed pandemic management.

Rapid diagnostic tests (RDTs) are an accurate and cost-effective means to administer widespread testing across any geographic region. RDTs can be used for rapid screening of active COVID-19 infections using antigen tests and monitoring of immunity and past infections through antibody testing.

Fionet’s combination of software and hardware is compatible with multiple COVID-19 test types from various manufacturers and easily integrates new and future tests as they come on the market.

Fionet has been proven on COVID-19 with recent deployment at the Toronto Pearson Airport, as part of a program to provide rapid on-site COVID-19 testing of passengers and airport staff for safer travel. Recently, FRR announced a partnership with LifeLabs, a Canadian medical laboratory leader, to provide nationwide, community-based rapid antigen testing utilizing the Fionet Platform8.

Effective and successful COVID-19 response requires urgent interruption of the chain of transmission through massive testing efforts, which in turn will prevent the emergence of new variants.

That, in addition to fast vaccination, is indispensable to bring the pandemic under control. Fionet allows for safe, accessible and high-quality testing of large populations now and in the future as we continue to fight to stop the COVID-19 pandemic.

Testing programs are a cornerstone of public health response and the need for more distributed testing continues to accelerate in both the private and public sectors, examples include testing requirements for entry of international travellers to the majority of countries and the Government of Ontario’s Rapid Antigen screening program for workplaces.

The Fionet Platform is an end-to-end, rapid testing and tracking solution for community-based or decentralized settings.

Fio Corporation developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management.

Relay Medical is focused on novel technologies in the diagnostics and AI data science sectors.

Relay Medical Corp (RELA) opened trading at C$0.54 per share.

More From The Market Herald

" BioHarvest Sciences (CSE:BHSC) appoints Steven Lehrer to its advisory board

BioHarvest Sciences (BHSC) has appointed Steven Lehrer as its newest advisory board member, effective immediately.
WOW! Unlimited Media - CEO, Michael Hirsh.

" Genius Brands to acquire WOW! Unlimited Media (TSXV:WOW)

Genius Brands is set to acquire WOW! Unlimited Media (WOW) for C$1.623 per share or $66 million.

" CloudMD (TSXV:DOC) Receives U.S. patent approval

CloudMD Software & Services Inc. (DOC) has received US patent approval for its Real Time Intervention Platform.

" NervGen Pharma (TSXV:NGEN) introduces Spinal Cord Injury Board

NervGen Pharma Corp. (NGEN) has introduced its Spinal Cord Injury (SCI) Clinical Advisory Board.